AIMS: Carbonic anhydrase (CA) isozymes IX and XII have been suggested to play a role in oncogenic processes. The aim of the present study was to investigate CA IX and XII expression in patients with ovarian tumours. METHODS AND RESULTS: A series of ovarian tumours was immunostained for CA IX and XII and the results were correlated with histopathological and clinical parameters. Most cases of borderline mucinous cystadenomas, mucinous cystadenocarcinomas and serous cystadenocarcinomas were moderately or strongly positive for CA IX. In malignant tumours, the staining was most prominent in hypoxic regions. Expression of CA XII was detected in all tumour categories, although the mean staining intensity was weaker than for CA IX in all groups except for clear cell carcinomas. CONCLUSIONS: The wide expression of CA IX and XII in ovarian tumours suggests that these isozymes could represent potential targets in ovarian cancer therapy. The expression pattern of CA IX suggests that it could also serve as a useful histopathological marker protein for hypoxia in malignant ovarian tumours.
AIMS: Carbonic anhydrase (CA) isozymes IX and XII have been suggested to play a role in oncogenic processes. The aim of the present study was to investigate CA IX and XII expression in patients with ovarian tumours. METHODS AND RESULTS: A series of ovarian tumours was immunostained for CA IX and XII and the results were correlated with histopathological and clinical parameters. Most cases of borderline mucinous cystadenomas, mucinous cystadenocarcinomas and serous cystadenocarcinomas were moderately or strongly positive for CA IX. In malignant tumours, the staining was most prominent in hypoxic regions. Expression of CA XII was detected in all tumour categories, although the mean staining intensity was weaker than for CA IX in all groups except for clear cell carcinomas. CONCLUSIONS: The wide expression of CA IX and XII in ovarian tumours suggests that these isozymes could represent potential targets in ovarian cancer therapy. The expression pattern of CA IX suggests that it could also serve as a useful histopathological marker protein for hypoxia in malignant ovarian tumours.
Authors: Amanda F Baker; Scott W Malm; Ritu Pandey; Cindy Laughren; Haiyan Cui; Denise Roe; Setsuko K Chambers Journal: Cancer Microenviron Date: 2015-05-22
Authors: Peter C Hart; Hilary A Kenny; Niklas Grassl; Karen M Watters; Lacey M Litchfield; Fabian Coscia; Ivana Blaženović; Lisa Ploetzky; Oliver Fiehn; Matthias Mann; Ernst Lengyel; Iris L Romero Journal: Cell Rep Date: 2019-12-17 Impact factor: 9.423
Authors: Christopher M Franke; Vivian W Gu; Benjamin G Grimm; Victoria C Cassady; Jeffrey R White; Ronald J Weigel; Mikhail V Kulak Journal: Oncogene Date: 2019-10-21 Impact factor: 9.867
Authors: Kristiina Nordfors; Joonas Haapasalo; Miikka Korja; Anssi Niemelä; Jukka Laine; Anna-Kaisa Parkkila; Silvia Pastorekova; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila; Hannu Haapasalo Journal: BMC Cancer Date: 2010-04-18 Impact factor: 4.430